• Danielle Jolla, United States says, "I love your online pharmacy Because of your quick shipping and reasonable prices."
  • Jill Barrella, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "I am very satisfied with IDM and plan on making more purchases in the future. IDMs prices are low which makes it very compelling to use over conventional pharmacies with high copays and more restrictions continually implemented."
  • Eric Gonzales, United States says, "The website is very user friendly, there is a lot of variety and checking out was easy."
  • Albert Martinez, United States says, "Very organized and efficient concerning delivery and products are great. Very satisfied, impressed with delivery and product."
  • Natalie Wallace, United States says, "I absolutely love getting my medications at a great price and I always get that here. And I recommend this site to my family and friends."
    • Just look at what our Tens of Thousands of Satisfied Customers say about us
    Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @ InternationalDrugMart.com.
    Get your instant Coupon now!
    Price challenge
    You can find the latest happening of our pharmacy Visit to discuss on various diseases and conditions
    Follow us on Twitter

      India's Ranbaxy gets US FDA nod to manufacture, market generic of GSK's Ceftin

      Posted Atmoney.cnn.com

      BANGALORE, Feb. 6, 2008 (Thomson Financial delivered by Newstex) -- India's Ranbaxy Laboratories Ltd said its US unit has received US FDA approval to manufacture and market the generic version of GlaxoSmithKline PLC's (NYSE:GSK) paediatric Anti-Bacterial drug Ceftin, Cefuroxime Axetil, for oral suspension in the 125mg/5ml and 250mg/5ml dosage form.

      The pharma major said the total annual market sales for Cefuroxime Axetil Suspension were 28.7 mln usd as per IMS Health (NYSE:RX) data, December 2007.

      Jim Meehan, vice president of sales and distribution for Ranbaxy's US unit, said: 'Ranbaxy is pleased to receive this approval for Cefuroxime Axetil Suspension that now allows us to be the only generic company to offer both dosage forms for a product that is highly prescribed.'

      Copyright Thomson Financial News Limited 2007. All rights reserved.

      The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.

      February 06, 2008


       

      Share this Article!

    Back to top^